TSX Venture: QPT
EDMONTON, Nov. 6, 2017 /CNW/ - Quest PharmaTech Inc.
(TSX-V: QPT) ("Quest" or the "Company"), a pharmaceutical company
developing and commercializing products to improve the quality of
life, today announced the results of its November 2, 2017 annual general meeting of
shareholders.
The Company is pleased to announce the following 5 directors
have been elected to the Company's Board of Directors:
Lorne Meikle, BA
J. Mark Lievonen, C.M., FCPA, FCA,
LLD
W. John Meekison, CPA, CMA, P.Log,
CIM
Shawn Lu, CIM, MFin
Madi R. Madiyalakan, Ph.D.
Mr. Meikle, Mr. Lievonen and Mr. Meekison are all independent
directors. Mr. Meikle is the Chairman of the Board. Mr.
Meekison is Chair of the Audit Committee. Mr. Lievonen is
Chair of the Governance Committee and Mr. Lu is Chair of the
Compensation Committee.
"We are pleased with the AGM results and wish to thank our
shareholders for their continuing support," said Dr. Madi R. Madiyalakan, Chief Executive Officer for
Quest. "I would also like to welcome our 2 newly elected
Board members, Mr. Lievonen and Mr. Meekison, who bring a wealth of
pharmaceutical and corporate finance experience to the Board.
Mr. Lievonen has over 30 years' experience in the biopharmaceutical
industry. From 1999 to 2016, Mr. Lievonen was the President
of Sanofi Pasteur Limited, the Canadian vaccine division of Sanofi,
a global pharmaceutical company. He was appointed to the
Order of Canada in 2015, named a
Chevalier de l'Ordre National de Mérite by the government of
France in 2007, and was inducted
into the Canadian Healthcare Marketing Hall of Fame in 2013.
Mr. Meekison is the Chief Financial Officer of Segra International
Corp., a private technology company servicing the cannabis
sector. From 2005 to 2016, Mr. Meekison was the Chief
Financial Officer and co-founder of iCo Therapeutics Inc., a
pharmaceutical development company. He is a former investment
banker with extensive experience in the areas of corporate finance,
capital markets and investment financing. With the strength
and experience of our re-elected Board members, Mr. Meikle, Mr. Lu
and myself, I am confident that Quest's Board of Directors will be
able to help the Company execute its business strategy to add value
to our shareholders."
Approximately 73,600,000 shares were voted for the Company's
shareholder meeting representing 44% of the Company's shares
eligible to vote. Shareholder's voted 99% in favor of all
meeting resolutions.
About Quest PharmaTech Inc.
Quest PharmaTech is a publicly traded; Canadian based
pharmaceutical company developing products to improve the quality
of life. The Company through its subsidiary, OncoQuest and its
Chinese joint venture, OncoVent, is developing antibody based
immunotherapeutic products for cancer. In addition, the Company
owns the Photodynamic Therapy technology for oncology and
dermatology applications, licensed to BioCeltran Co., Ltd., a Korea
based company (Bioceltran). Quest has an ownership interest
in Bioceltran, which is focused on SP Technology™ for transdermal
delivery of drugs and photosensitizers for pharmaceutical and
cosmetic purposes. Quest through another subsidiary, Madenco
Biosciences, also markets consumer health products worldwide,
including Bellus Skin™ serum, a premium anti-wrinkle skin care
product licensed from Korea. Quest is also developing an
antibody licensed from University of
Nebraska, Mab AR 9.6 against truncated O-glycan on MUC16,
for targeted cancer therapy applications.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Internet: www.questpharmatech.com
SOURCE Quest PharmaTech Inc.